#United States #New York #Class Action #Intellia Therapeutics #NTLA

Update on the Intellia Therapeutics Class Action Lawsuit

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is currently embroiled in a class action lawsuit, with significant implications for its shareholders. The Gross Law Firm has recently issued a notice informing investors about the ongoing proceedings and the essential deadlines that they must be aware of.

What Happened?

The class action encompasses shares purchased between July 30, 2024, and January 8, 2025. During this time, substantial information regarding the company’s NTLA-3001 research for treating alpha-1 antitrypsin deficiency (AATD)-related lung disease was inadequately disclosed to the investors. Notably, the defendants are accused of lacking transparency regarding the declining demand for viral-based gene editing technologies, shifting focus instead towards non-viral delivery methods which present more cost-effective and efficient options.

On January 9, 2025, Intellia announced a major restructuring of the company, which included ceasing all NTLA-3001 related research and reducing its workforce by 27%. Following this revelation, Intellia's stock price dropped significantly, illustrating the impact of the halted studies on investor confidence.

The Class Action Process

Shareholders who acquired NTLA shares during the specified period have been encouraged to come forward. While it’s not mandatory to be appointed as a lead plaintiff to be part of the recovery process, those interested can connect with The Gross Law Firm for potential involvement.

The deadline to apply for lead plaintiff status is April 14, 2025. It is critical for affected investors to take appropriate action before this date. Once registered, investors will benefit from continuous updates through portfolio monitoring software designed to keep them informed throughout the lawsuit's progression.

Why Join the Class Action?

Joining the class action offers investors a collective means to address grievances related to misleading statements that contributed to inflated stock prices before the crucial information was disclosed. The Gross Law Firm is recognized nationally for its commitment to protecting investor rights and ensuring that corporations are held accountable for illicit practices. They aim to assist all investors affected by the deceptive actions of businesses, further reinforcing corporate responsibility.

Next Steps for Intellia Shareholders

It's imperative for shareholders to register their information if they bought shares during the class action’s stated timeframe. Through this action, they can not only pave their way to participating in the recovery process but also ensure they remain updated about any developments in the case.

With the deadline looming, it is advised not to wait until the last moment to act. Investors can submit their information through the firm’s online form to safeguard their interests.

Contact Information

For further inquiries, shareholders should directly reach out to The Gross Law Firm. Their contact coordinates are:

• - Phone: (646) 453-8903
• - Email: info@grosslawfirm.com
• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018

In conclusion, the Intellia Therapeutics class action is a crucial matter for affected investors, and timely action can make a significant difference in how their claims are handled. The effective management of these proceedings not only serves the individual investors but also promotes better business transparency in the biotech sector.